Medexus Pharmaceuticals Inc (TSE:MDP)
TSX:MDP
Want to see TSE:MDP full AI Analyst Report?
Top Page
Medexus Pharmaceuticals Inc
(TSX:MDP)
Select Model
Select Model
Rating:66Neutral
Price Target:
C$4.50
▲(13.35% Upside)
Action:Reiterated
Date:04/18/26
The score is driven primarily by improving fundamentals—especially strong free cash flow and a materially improved leverage profile—supported by an established upward technical trend. These positives are tempered by very expensive valuation (high P/E), overextended momentum signals (RSI/Stoch), and earnings-call headwinds including YoY revenue/EBITDA declines despite encouraging GRAFAPEX adoption and guidance.
Positive Factors
Consistent free cash flow
Sustained positive operating and free cash flow provides durable internal funding for launches, working capital and debt reduction. Strong cash conversion reduces reliance on external financing and supports capital allocation choices that can underwrite growth and margin improvement over the next 2–6 months.
Negative Factors
Year-over-year revenue decline
Material YoY revenue declines reflect structural demand loss in legacy products due to generic competition and license returns. This shrinks the baseline revenue base and increases reliance on newer launches to replace revenues, raising execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent free cash flow
Sustained positive operating and free cash flow provides durable internal funding for launches, working capital and debt reduction. Strong cash conversion reduces reliance on external financing and supports capital allocation choices that can underwrite growth and margin improvement over the next 2–6 months.
Read all positive factors
Medexus Pharmaceuticals Inc (MDP) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$132.75M
Dividend YieldN/A
Average Volume (3M)46.68K
Price to Earnings (P/E)―
Beta (1Y)0.86
Revenue Growth-7.44%
EPS Growth-108.29%
CountryCA
Employees82
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.01
Shares Outstanding32,300,380
10 Day Avg. Volume30,861
30 Day Avg. Volume46,683
Financial Highlights & Ratios
PEG Ratio1.50
Price to Book (P/B)1.19
Price to Sales (P/S)0.32
P/FCF Ratio1.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.26
Revenue Forecast (FY)C$114.60M
Medexus Pharmaceuticals Inc Business Overview & Revenue Model
Company Description
Medexus Pharmaceuticals Inc. operates as a specialized pharmaceutical company, conducting its business across Canada and the United States. The firm's strategic focus encompasses critical therapeutic domains such as oncology, hematology, rheumatol...
How the Company Makes Money
Medexus makes money primarily by selling prescription pharmaceutical products it commercializes (i.e., revenue is generated from product sales to healthcare channels such as wholesalers, specialty pharmacies, hospitals, and other distribution/cust...
Medexus Pharmaceuticals Inc Earnings Call Summary
Earnings Call Date:Feb 11, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Jun 25, 2026
Earnings Call Sentiment Neutral
The call highlighted meaningful early commercial traction for GRAFAPEX (formulary uptake, reorder rates, improving patient demand and a FY26 revenue outlook of $11M–$12M), margin improvements, strong operating cash generation, reduced net debt and cost savings initiatives (IXINITY). Offsetting these positives were year-over-year declines in total net revenue, adjusted EBITDA and net income driven by Rupall generic competition, the return of Gleolan, and launch investments that have so far slightly exceeded GRAFAPEX product-level revenue. Management emphasized improving trends, cash flow strength, and financing flexibility that position the company to scale commercialization. Overall, the positives around GRAFAPEX momentum and liquidity improvements balance the near-term earnings and revenue headwinds, leading to a neutral assessment.Positive Updates
GRAFAPEX Early Commercial Adoption
32% of 180 U.S. transplant centers (57 institutions) have ordered GRAFAPEX and 77% of those centers have reordered; product-level patient demand rebounded strongly in January 2026 and product-level net revenue for the 9 months ending Dec 31, 2025 totaled $8.2M.
Negative Updates
YoY Net Revenue Decline
Total net revenue for fiscal Q3 '26 was $25.3M, down $4.7M or approximately -15.7% versus $30.0M in fiscal Q3 '25, driven in part by reduced Rupall sales and the return of Gleolan to its licensor.
Read all updates
Q3-2026 Updates
Positive
Negative
GRAFAPEX Early Commercial Adoption
32% of 180 U.S. transplant centers (57 institutions) have ordered GRAFAPEX and 77% of those centers have reordered; product-level patient demand rebounded strongly in January 2026 and product-level net revenue for the 9 months ending Dec 31, 2025 totaled $8.2M.
Read all positive updates
Company Guidance
Management guided that GRAFAPEX will be accretive to quarterly operating cash flow starting in fiscal Q4 ’26 and is expected to generate product‑level net revenue of $11–$12 million for fiscal 2026; through the nine months ended Dec 31, 2025 they recognized $8.2M of GRAFAPEX product‑level revenue versus $8.5M invested in the launch year‑to‑date, Q3 ’26 product‑level net revenue was $2.0M (underlying patient demand $2.6M), and they expect patient demand in fiscal Q4 ’26 of roughly $3–$4M (prior quarters: Q1 $2.2M, Q2 $2.1M, Q3 $2.6M) which, given wholesaler inventory, implies Q4 product‑level net revenue of $3–$4M; adoption metrics include 32% of the 180 U.S. transplant centers (57 centers) having ordered with a 77% reorder rate, roughly one‑third on formulary/one‑third under review/one‑third in process, and an adult/pediatric split of ~85%/15% (Medicare NTAP add‑on ≈ $21,000 covering ~30% of adult patients); SG&A related to GRAFAPEX is expected to rise modestly back toward $3–$4M and nearer $4M in fiscal ’27; company‑level Q3 results and balance‑sheet metrics cited alongside this guidance were: net revenue $25.3M (vs $30.0M y/y), gross profit $13.6M (gross margin 53.6% vs 50.7% y/y), adjusted EBITDA $4.5M (vs $5.8M), operating income $1.7M (vs $2.1M), net income $0.1M (vs $0.7M), operating cash flow $7.8M (vs $6.7M), average cash from operations $4.3M/quarter since launch, cash on hand $15M (Dec 31, 2025), net debt $10.4M (down from $13.2M Mar 31, 2025), 201,500 shares repurchased, a new credit facility that reduced quarterly principal repayments from $3.3M to $0.5M, a $1.2M committed IXINITY process investment (to be paid in fiscal ’26) and a 30% reduction in IXINITY product‑level COGS since fiscal Q1 ’21.Medexus Pharmaceuticals Inc Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
68
Positive
Cash Flow
79
Positive
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 99.43M | 108.33M | 108.10M | 76.70M | 79.66M | 74.36M |
| Gross Profit | 53.57M | 56.58M | 60.04M | 37.93M | 42.01M | 29.44M |
| EBITDA | 15.80M | 16.81M | 14.65M | 14.55M | -23.61M | 3.78M |
| Net Income | -272.00K | 2.25M | 1.22M | -2.88M | -28.26M | -4.70M |
Balance Sheet | ||||||
| Total Assets | 154.98M | 171.84M | 161.33M | 139.22M | 148.51M | 122.81M |
| Cash, Cash Equivalents and Short-Term Investments | 14.97M | 23.97M | 13.07M | 10.02M | 18.70M | 5.23M |
| Total Debt | 25.35M | 37.18M | 70.08M | 54.86M | 44.87M | 38.81M |
| Total Liabilities | 102.77M | 119.69M | 138.88M | 121.43M | 130.50M | 98.53M |
| Stockholders Equity | 52.21M | 52.14M | 22.45M | 17.79M | 18.02M | 24.28M |
Cash Flow | ||||||
| Free Cash Flow | 17.16M | 21.31M | -1.81M | -8.89M | -5.72M | -3.54M |
| Operating Cash Flow | 17.36M | 24.03M | -1.44M | -1.18M | 5.04M | -3.43M |
| Investing Cash Flow | -11.48M | -6.00M | -1.72M | -8.20M | -11.70M | -30.32M |
| Financing Cash Flow | 418.00K | 796.00K | 6.41M | 663.00K | 18.68M | 15.42M |
Medexus Pharmaceuticals Inc Technical Analysis
Positive
3.97
Price Trends
3.97
Positive
3.51
Positive
3.16
Positive
Market Momentum
0.05
Negative
57.44
Neutral
51.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MDP, the sentiment is Positive. The current price of 3.97 is below the 20-day moving average (MA) of 3.98, below the 50-day MA of 3.97, and above the 200-day MA of 3.16, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 57.44 is Neutral, neither overbought nor oversold. The STOCH value of 51.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MDP.
Medexus Pharmaceuticals Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | C$159.56M | 17.50 | 22.05% | 1.60% | 20.13% | 17.08% | |
66 Neutral | C$132.75M | -346.61 | -0.52% | ― | -7.44% | -108.29% | |
52 Neutral | C$61.92M | -2.80 | -21.73% | ― | 31.50% | 17.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | C$10.44M | -1.53 | -18.39% | ― | 44.34% | -281.74% | |
41 Neutral | C$17.95M | -5.34 | -256.01% | ― | ― | -28.29% | |
41 Neutral | C$45.49M | -4.72 | ― | ― | -62.34% | 9.80% |
* Healthcare Sector Average
TSE:MDP
Medexus Pharmaceuticals Inc
4.11
0.71
20.88%
TSE:MPH
Medicure
1.00
-0.27
-21.26%
TSE:RX
Biosyent
13.95
2.34
20.11%
TSE:VEXT
Vext Science
0.25
0.11
85.19%
TSE:VM
Voyageur Pharmaceuticals
0.10
-0.15
-60.00%
TSE:BNXT
BioNxt Solutions
0.35
-0.17
-32.69%
Medexus Pharmaceuticals Inc Corporate Events
Business Operations and StrategyStock BuybackProduct-Related Announcements
Medexus Advances U.S. GRAFAPEX Rollout While Streamlining Capital Structure
Positive
Apr 15, 2026
Medexus Pharmaceuticals reported continued progress in the U.S. commercialization of GRAFAPEX, with 56 transplant centers granting formulary inclusion and 64 centers placing orders as of March 31, 2026. Management said these adoption metrics align...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.